Reasons Why Post-Trial Access to Trial Drugs Should, or Need not be Ensured to Research Participants: A Systematic Review

被引:60
|
作者
Sofaer, Neema [1 ]
Strech, Daniel [2 ]
机构
[1] Kings Coll London, Sch Law, Ctr Med Law & Eth, London WC2R 2LS, England
[2] Hannover Med Sch, CELLS, Inst Hist Eth & Philosophy Med, Hannover, Germany
基金
英国惠康基金;
关键词
CLINICAL-TRIALS; ANTIRETROVIRAL THERAPY; ETHICAL-ISSUES; ANCILLARY-CARE; PREVENTION; PROVISION; HIV/AIDS; JUSTICE; AIDS;
D O I
10.1093/phe/phr013
中图分类号
B82 [伦理学(道德学)];
学科分类号
摘要
Background: researchers and sponsors increasingly confront the issue of whether participants in a clinical trial should have post-trial access (PTA) to the trial drug. Legislation and guidelines are inconsistent, ambiguous or silent about many aspects of PTA. Recent research highlights the potential importance of systematic reviews (SRs) of reason-based literatures in informing decision-making in medicine, medical research and health policy. Purpose: to systematically review reasons why drug trial participants should, or need not be ensured PTA to the trial drug and the uses of such reasons. Data sources: databases in science/medicine, law and ethics, thesis databases, bibliographies, research ethics books and included publications' notes/bibliographies. Publication selection: a publication was included if it included a reason as above. See article for detailed inclusion conditions. Data extraction and analysis: two reviewers extracted and analyzed data on publications and reasons. Results: of 2060 publications identified, 75 were included. These mentioned reasons based on morality, legality, interests/incentives, or practicality, comprising 36 broad (235 narrow) types of reason. None of the included publications, which included informal reviews and reports by official bodies, mentioned more than 22 broad (59 narrow) types. For many reasons, publications differed about the reason's interpretation, implications and/or persuasiveness. Publications differed also regarding costs, feasibility and legality of PTA. Limitations: reason types could be applied differently. The quality of reasons was not measured. Conclusion: this review captured a greater variety of reasons and of their uses than any included publication. Decisions based on informal reviews or sub-sets of literature are likely to be biased. Research is needed on PTA ethics, costs, feasibility and legality and on assessing the quality of reason-based literature.
引用
收藏
页码:160 / 184
页数:25
相关论文
共 20 条
  • [1] Reciprocity and post-trial access for participants in antiretroviral therapy trials
    Merritt, Maria
    Grady, Christine
    AIDS, 2006, 20 (14) : 1791 - 1794
  • [2] Human dignity as a basis for providing post-trial access to healthcare for research participants: a South African perspective
    Andanda, Pamela
    Wathuta, Jane
    MEDICINE HEALTH CARE AND PHILOSOPHY, 2018, 21 (01) : 139 - 155
  • [3] Human dignity as a basis for providing post-trial access to healthcare for research participants: a South African perspective
    Pamela Andanda
    Jane Wathuta
    Medicine, Health Care and Philosophy, 2018, 21 : 139 - 155
  • [4] Implementing post-trial access plans for HIV prevention research
    Paul, Amy
    Merritt, Maria W.
    Sugarman, Jeremy
    JOURNAL OF MEDICAL ETHICS, 2018, 44 (05) : 354 - 358
  • [5] Disseminating results to clinical trial participants: a qualitative review of patient understanding in a post-trial population
    Darbyshire, Julie Lorraine
    Price, Hermione Clare
    BMJ OPEN, 2012, 2 (05):
  • [6] Need for greater post-trial support for clinical trial participants assessing high-risk, irreversible treatments
    Harris, Alex
    Gilbert, Frederic
    JOURNAL OF MEDICAL ETHICS, 2024,
  • [7] Post-trial access to investigational drugs in India: addressing challenges in the regulatory framework
    Mehrotra, Nidhi
    Manchikanti, Padmavati
    MEDICAL LAW REVIEW, 2024, 32 (01) : 20 - 41
  • [8] Availability of post-trial access in clinical trials: a review of clinical trial protocols submitted to the research ethics board of the University of the Philippines Manila
    Jimenez, Edlyn B.
    Virtudazo, Jessa Mae P.
    Torres, Cristina E.
    Bernabe, Rosemarie dlC
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (11) : 1849 - 1855
  • [9] Post-trial access to tested interventions: The views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study
    Pace, Christine
    Grady, Christine
    Wendler, David
    Bebchuk, Judith D.
    Tavel, Jorge A.
    McNay, Laura A.
    Forster, Heidi P.
    Killen, Jack
    Emanuel, Ezekiel J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (09) : 837 - 841
  • [10] Investigation of post-trial access views among study participants and stakeholders using photovoice and semistructured interviews
    Ngwenya, Nothando
    Iwuji, Collins
    Petersen, Nabeel
    Myeni, Nompilo
    Nxumalo, Samukelisiwe
    Ngema, Ursula
    Seeley, Janet
    JOURNAL OF MEDICAL ETHICS, 2022, 48 (10) : 712 - 717